Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cancer Lett. 2014 Apr 10;345(2):249-57. doi: 10.1016/j.canlet.2013.09.001. Epub 2013 Sep 7.
Growing evidence from epidemiologic and preclinical studies suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers, including esophageal, gastric, pancreatic, colorectal cancer, and hepatocellular carcinoma. However, there is also evidence indicating the absence of this benefit. The exact mechanism of NSAIDs' action on GI tumors is not known. Although some studies have suggested inhibition of carcinogenesis by NSAIDs through suppression effect on inflammation-associated cyclooxygenase-2 (COX-2) expression, other studies have suggested COX-2-independent mechanisms. Herein, we summarize the current state of-the-science regarding NSAID benefit for patients with GI cancers.
越来越多的流行病学和临床前研究证据表明，非甾体抗炎药（NSAIDs）可降低胃肠道（GI）癌症的风险，包括食管癌、胃癌、胰腺癌、结直肠癌和肝细胞癌。然而，也有证据表明它们没有这种益处。NSAIDs 对 GI 肿瘤作用的确切机制尚不清楚。尽管一些研究表明 NSAIDs 通过抑制与炎症相关的环氧化酶-2（COX-2）表达来抑制致癌作用，但其他研究表明存在 COX-2 非依赖性机制。本文总结了目前关于 NSAIDs 对 GI 癌症患者获益的科学现状。
